Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
14.80
-0.11 (-0.74%)
At close: Apr 24, 2026, 4:00 PM EDT
14.52
-0.28 (-1.89%)
After-hours: Apr 24, 2026, 7:55 PM EDT
Adlai Nortye Employees
Adlai Nortye had 109 employees as of December 31, 2025. The number of employees decreased by 14 or -11.38% compared to the previous year.
Employees
109
Change (1Y)
-14
Growth (1Y)
-11.38%
Revenue / Employee
$45,872
Profits / Employee
-$325,945
Market Cap
592.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 109 | -14 | -11.38% |
| Dec 31, 2024 | 123 | -4 | -3.15% |
| Dec 31, 2023 | 127 | -2 | -1.55% |
| Jun 30, 2023 | 130 | - | - |
| Mar 31, 2023 | 129 | - | - |
| Dec 31, 2022 | 129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Arvinas | 246 |
| ProKidney | 231 |
| CorMedix | 191 |
| Prime Medicine | 146 |
| Kyverna Therapeutics | 130 |
| Aclaris Therapeutics | 73 |
| Zevra Therapeutics | 61 |
ANL News
- 9 days ago - Adlai Nortye Announces $150.0 Million Private Placement Equity Financing - GlobeNewsWire
- 2 months ago - Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewsWire
- 2 months ago - Adlai Nortye Announces $140.0 Million Private Placement Equity Financing - GlobeNewsWire
- 4 months ago - Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewsWire
- 6 months ago - Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 2 years ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire